Bio-Rad Launches CFX Duet Real-Time PCR System
BioRad Laboratories CFX Duet System is designed to help researchers develop singleplex and duplex quantitative polymerase chain reaction assays.
Bio-Rad Laboratories announced the launch of the CFX Duet Real-Time PCR System on May 26, 2022. The CFX Duet is designed to help researchers develop singleplex and duplex quantitative polymerase chain reaction (qPCR) assays.
According to a company press release, the CFX Duet is a two-color system that is factory calibrated for common dyes, allowing for the precise quantification of up to two targets in genotyping and multiple gene expression analysis without the need for passive reference dies. The device features thermal gradient functionality to enable optimization in fewer runs.
An additional fluorescence resonance energy transfer (FRET) mode supports protein melt analysis for basic protein characterization. The device uses CFX Maestro Software for easy experimental setup and analysis, allowing it to deliver customized reports without exporting data to other programs.
“We are pleased to expand our portfolio of qPCR instruments with the CFX Duet System to help customers run singleplex and duplex assays with a software that matches the robust thermal capabilities of our premium CFX Opus formats.” said Steven Blakely, director for gene expression and software technology, Bio-Rad, in the press release. “The versatile CFX Duet System allows users to quickly get started with gene expression, genotyping, quantification and thermal gradient optimization, as well as protein characterization using FRET.”
Source: Bio-Rad Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
